BioSpace News Archive

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, held a virtual ground-breaking ceremony today to celebrate the start of its large scale cell culture expansion project

Acumen Analytics, the leader in advanced analytics, Blockchain and AI solutions enabling data transformation to drive measurable business outcomes, announced a multi-year collaboration with Phylloceuticals, a privately held, global technology company dedicated to providing medicine to underserved areas of the world.

ZyVersa is well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome inhibitor, IC 100, which has potential to treat a broad range of inflammatory diseases IC 100 uniquely targets ASC to inhibit multiple types of inflammasomes, and thereby acts independently of the triggers and sensors that cause inflammatory diseases

Sheldon Moberg joins Bexson as Senior VP Drug Delivery, where he’ll lead the development of proprietary devices that can make controlled substances and other therapies more accessible.

Peer-reviewed article confirms the quality and robustness of clinical data and the good safety and durable efficacy of once daily oral ABX464 in moderate to severe ulcerative colitis (UC) patients Recruitment of subsequent phase 2b induction study in 254 patients with ABX464 in UC completed in December 2020 and top-line results are expected in Q2 2021 Abivax is preparing to move its lead drug-candidate ABX464 into a phase 3 clinical program in ulcerative colitis and to initiate a phase

Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2021 ADDF-Harrington Scholar Award .

A detailed analysis of mental health treatment trends during the COVID-19 pandemic found a 7% increase in visits during the initial shelter-in-place period in 2020, compared with the same 3-month period in 2019.

Battelle research shows that analyzing wastewater for the presence of the virus that causes COVID-19 can pinpoint specific neighborhoods that are hotspots for viral outbreaks.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred Stock.

BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71 million in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads.